It should be noted that in most cancer patients, the PD-1/PD-L1 pathway is not the only speed-limiting factor of anti-tumor immunity, so blocking the PD-1/PD-L1 pathway alone is not sufficient to elicit effective antitumor immune response (79). The gene discussed is CD274; the disease is neoplasm.